Zhe-Sheng Chen

List of Publications by Year in Descending Order

369 papers	14,921 citations	59 h-index	109 g-index
405 ext. papers	17,742 ext. citations	8.1 avg, IF	6.78 L-index

#	Paper	IF	Citations
369	Detailed resume of RNA m6A demethylases. *Acta Pharmaceutica Sinica B*, **2022**,	15.5	1
368	Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 3	12.8	9
367	Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin.. *European Journal of Medicinal Chemistry*, **2022**, 231, 114155	6.8	2
366	Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.. *Pharmaceutical Research*, **2022**, 1	4.5	3
365	PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study.. *Molecular Cancer*, **2022**, 21, 40	42.1	0
364	Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.. *Molecular Cancer*, **2022**, 21, 43	42.1	0
363	Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.. *Molecular Cancer*, **2022**, 21, 37	42.1	2
362	Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p.. *Molecular Cancer*, **2022**, 21, 12	42.1	9
361	Paclitaxel and chemoresistance **2022**, 251-267		1
360	Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy **2022**, 269-286		
359	Research progress in overcoming ibrutinib drug resistance.. *Drugs of Today*, **2022**, 58, 85-94	2.5	
358	Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.. *Drugs of Today* , **2022**, 58, 175-185	2.5	0
357	Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances.. *Drugs of Today*, **2022**, 58, 117-132	2.5	0
356	Therapeutic Implication of Oxidative Stress Regulators in Drug-Resistant Cancers **2022**, 1-20		
355	m6A modification: recent advances, anticancer targeted drug discovery and beyond.. *Molecular Cancer*, **2022**, 21, 52	42.1	6
354	Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells.. *Frontiers in Pharmacology*, **2022**, 13, 843829	5.6	1
353	Phytochemical Delivery Through Transferosome (Phytosome): An Advanced Transdermal Drug Delivery for Complementary Medicines.. *Frontiers in Pharmacology*, **2022**, 13, 850862	5.6	5

352	Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?. *Frontiers in Pharmacology*, **2022**, 13, 843110	5.6	0
351	Proteomics technologies for cancer liquid biopsies.. *Molecular Cancer*, **2022**, 21, 53	42.1	5
350	The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter.. *Frontiers in Pharmacology*, **2022**, 13, 861642	5.6	0
349	Fiber-Optic Theranostics (FOT): Interstitial Fiber-Optic Needles for Cancer Sensing and Therapy.. *Advanced Science*, **2022**, e2200456	13.6	3
348	The Discovery of Novel PGK1 Activators as Apoptotic Inhibiting and Neuroprotective Agents.. *Frontiers in Pharmacology*, **2022**, 13, 877706	5.6	0
347	Mechanism of N-Methyl-N-Nitroso-Urea-Induced Gastric Precancerous Lesions in Mice.. *Journal of Oncology*, **2022**, 2022, 3780854	4.5	
346	Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges.. *Frontiers in Oncology*, **2022**, 12, 867655	5.3	2
345	Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure.. *Signal Transduction and Targeted Therapy*, **2022**, 7, 89	21	0
344	The Potential Role of Exosomes in the Treatment of Brain Tumors, Recent Updates and Advances.. *Frontiers in Oncology*, **2022**, 12, 869929	5.3	0
343	Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells.. *Frontiers in Pharmacology*, **2022**, 13, 867128	5.6	0
342	An Ayurgenomics Approach: Prakriti-Based Drug Discovery and Development for Personalized Care.. *Frontiers in Pharmacology*, **2022**, 13, 866827	5.6	
341	CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.. *Molecular Cancer*, **2022**, 21, 103	42.1	3
340	2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update.. *Frontiers in Pharmacology*, **2022**, 13, 899633	5.6	5
339	The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells.. *Frontiers in Oncology*, **2022**, 12, 855570	5.3	0
338	Microbiota in health and diseases.. *Signal Transduction and Targeted Therapy*, **2022**, 7, 135	21	28
337	Tisotumab vedotin for the treatment of cervical carcinoma.. *Drugs of Today*, **2022**, 58, 213-222	2.5	1
336	Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.. *Molecular Cancer*, **2022**, 21, 112	42.1	2
335	Therapeutic implication of carbon monoxide in drug resistant cancers.. *Biochemical Pharmacology*, **2022**, 201, 115061	6	0

334	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer.. *Nature Communications*, **2022**, 13, 2672	17.4	6
333	Quercetin ameliorates oxidative stress-induced cell apoptosis of seminal vesicles via activating Nrf2 in type 1 diabetic rats. *Biomedicine and Pharmacotherapy*, **2022**, 151, 113108	7.5	4
332	Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 374	12.8	0
331	Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer. *Journal of Medicinal Chemistry*, **2021**, 64, 17346-17365	8.3	3
330	Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. *Frontiers in Pharmacology*, **2021**, 12, 732403	5.6	2
329	Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis. *Annals of the Rheumatic Diseases*, **2021**,	2.4	1
328	Podophyllum hexandrum and its active constituents: Novel radioprotectants.. *Biomedicine and Pharmacotherapy*, **2021**, 146, 112555	7.5	1
327	Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions. *Drugs of Today*, **2021**, 57, 621-629	2.5	2
326	Ginsenoside Rg3 Promotes Cell Growth Through Activation of mTORC1. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 730309	5.7	2
325	Cycloruthenated Self-Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers. *Advanced Materials*, **2021**, 34, e2100245	24	1
324	Extracellular Vesicles in Acute Leukemia: A Mesmerizing Journey With a Focus on Transferred microRNAs. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 766371	5.7	1
323	Natural Products: A Promising Therapeutics for Targeting Tumor Angiogenesis. *Frontiers in Oncology*, **2021**, 11, 772915	5.3	2
322	RNA methylation and cancer treatment. *Pharmacological Research*, **2021**, 174, 105937	10.2	2
321	Receptors and ligands for herpes simplex viruses: Novel insights for drug targeting. *Drug Discovery Today*, **2021**, 27, 185-185	8.8	2
320	Discovery of the Triazolo[1,5-]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. *Journal of Medicinal Chemistry*, **2021**, 64, 16187-16204	8.3	5
319	Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. *Protein and Cell*, **2021**, 12, 586-591	7.2	8
318	OGP46 Induces Differentiation of Acute Myeloid Leukemia Cells via Different Optimal Signaling Pathways. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 652972	5.7	3
317	The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 649434	5.7	2

316	Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 640957	5.7	2
315	Therapeutic strategies to overcome taxane resistance in cancer. *Drug Resistance Updates*, **2021**, 55, 100754	23.2	27
314	Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. *European Journal of Medicinal Chemistry*, **2021**, 216, 113316	6.8	4
313	Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. *Biomedicine and Pharmacotherapy*, **2021**, 136, 111223	7.5	6
312	Mechanisms of thrombosis and research progress on targeted antithrombotic drugs. *Drug Discovery Today*, **2021**, 26, 2282-2302	8.8	8
311	A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study. *Cancers*, **2021**, 13,	6.6	1
310	Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor. *Recent Patents on Anti-Cancer Drug Discovery*, **2021**, 16, 44-53	2.6	
309	Natural Product as Substrates of ABC Transporters: A Review. *Recent Patents on Anti-Cancer Drug Discovery*, **2021**, 16, 222-238	2.6	5
308	The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy. *Drug Discovery Today*, **2021**, 26, 1293-1301	8.8	5
307	AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer. *Frontiers in Oncology*, **2021**, 11, 680663	5.3	2
306	Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19. *Frontiers in Public Health*, **2021**, 9, 671788	6	5
305	Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. *Drug Discovery Today*, **2021**, 26, 1284-1292	8.8	25
304	Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. *Frontiers in Immunology*, **2021**, 12, 658519	8.4	24
303	Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). *Journal of Medicinal Chemistry*, **2021**, 64, 9120-9140	8.3	5
302	The role of endolysosomal trafficking in anticancer drug resistance. *Drug Resistance Updates*, **2021**, 57, 100769	23.2	7
301	Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. *Drug Resistance Updates*, **2021**, 57, 100770	23.2	14
300	Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 697927	5.7	0
299	Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens. *Frontiers in Pharmacology*, **2021**, 12, 720726	5.6	24

298	The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy. *Drug Discovery Today*, **2021**, 26, 490-502	8.8	9
297	Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). *Medicinal Research Reviews*, **2021**, 41, 525-555	14.4	54
296	Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation Evaluation of intestinal absorption and anti-cancer activity. *Journal of Molecular Liquids*, **2021**, 327, 114866	6	3
295	The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML **2021**,		
294	Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. *Drug Resistance Updates*, **2021**, 54, 100743	23.2	48
293	Tepotinib hydrochloride for the treatment of non-small cell lung cancer. *Drugs of Today*, **2021**, 57, 265-275	2.5	1
292	Lurbinectedin for the treatment of small cell lung cancer. *Drugs of Today*, **2021**, 57, 377-385	2.5	0
291	OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. *Frontiers in Pharmacology*, **2021**, 12, 620874	5.6	6
290	The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
289	Overexpression of ABCC1 Confers Drug Resistance to Betulin. *Frontiers in Oncology*, **2021**, 11, 640656	5.3	5
288	Insights on the structure-function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies. *MedComm*, **2021**, 2, 221-235	2.2	3
287	Long noncoding RNAs have pivotal roles in chemoresistance of acute myeloid leukemia. *Drug Discovery Today*, **2021**, 26, 1735-1743	8.8	8
286	Recent progress on targeting leukemia stem cells. *Drug Discovery Today*, **2021**, 26, 1904-1913	8.8	0
285	Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. *Bosnian Journal of Basic Medical Sciences*, **2021**,	3.3	
284	Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin. *Experimental Cell Research*, **2021**, 405, 112728	4.2	2
283	CMP25, a synthetic new agent, targets multidrug resistance-associated protein 7 (MRP7/ABCC10). *Biochemical Pharmacology*, **2021**, 190, 114652	6	2
282	ATP-binding cassette (ABC) transporters in cancer: A review of recent updates. *Journal of Evidence-Based Medicine*, **2021**, 14, 232-256	6.1	6
281	Novel nanomedicines to overcome cancer multidrug resistance. *Drug Resistance Updates*, **2021**, 58, 100777	23.2	20

280	MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer. *Molecular Cancer*, **2021**, 20, 118	42.1	1
279	Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 14895-14911	8.3	6
278	CUL4 Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival. *American Journal of Pathology*, **2021**, 191, 1638-1650	5.8	
277	Drug resistance: from bacteria to cancer.. *Molecular Biomedicine*, **2021**, 2, 27	3.1	2
276	Formulation and characterization of oleic acid magnetic PEG PLGA nanoparticles for targeting glioblastoma multiforme. *Journal of Magnetism and Magnetic Materials*, **2021**, 533, 167970	2.8	5
275	Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. *Frontiers in Oncology*, **2021**, 11, 731260	5.3	1
274	The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance. *International Journal of Biological Sciences*, **2021**, 17, 2652-2665	11.2	2
273	Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells.. *MedComm*, **2021**, 2, 765-777	2.2	4
272	Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 607275	5.7	5
271	Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter. *Frontiers in Oncology*, **2020**, 10, 574861	5.3	8
270	M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. *Frontiers in Oncology*, **2020**, 10, 674	5.3	13
269	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells. *Frontiers in Oncology*, **2020**, 10, 700	5.3	18
268	Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. *Cancer Communications*, **2020**, 40, 285-300	9.4	14
267	Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. *Frontiers in Oncology*, **2020**, 10, 228	5.3	10
266	Synthesis and Cytotoxicity Studies of Stilbene Long-Chain Fatty Acid Conjugates. *Journal of Natural Products*, **2020**, 83, 1563-1570	4.9	4
265	Long non-coding RNAs regulate drug resistance in cancer. *Molecular Cancer*, **2020**, 19, 54	42.1	62
264	ABCG2 Overexpression Contributes to Pevonedistat Resistance. *Cancers*, **2020**, 12,	6.6	9
263	Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells. *Frontiers in Oncology*, **2020**, 10, 932	5.3	3

262	Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer. *Journal of Medicinal Chemistry*, **2020**, 63, 8157-8178	8.3	11
261	Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor. *Biochemical Pharmacology*, **2020**, 175, 113848	6	13
260	Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor. *Experimental Cell Research*, **2020**, 388, 111858	4.2	11
259	Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. *Cancers*, **2020**, 12,	6.6	29
258	Lipid-Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo. *Cancers*, **2020**, 12,	6.6	3
257	Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	20
256	Recent progress in antitumor functions of the intracellular antibodies. *Drug Discovery Today*, **2020**, 25, 1109-1120	8.8	5
255	Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. *Cancers*, **2020**, 12,	6.6	24
254	Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. *Drug Resistance Updates*, **2020**, 49, 100681	23.2	93
253	The PI3K subunits, P110□and P110□are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. *Molecular Cancer*, **2020**, 19, 10	42.1	41
252	The combination of disulfiram and copper for cancer treatment. *Drug Discovery Today*, **2020**, 25, 1099-1108	8.8	34
251	Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells. *Experimental Cell Research*, **2020**, 391, 111987	4.2	5
250	Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue. *Journal of Medicinal Chemistry*, **2020**, 63, 5458-5476	8.3	15
249	Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells. *Cancer Science*, **2020**, 111, 2872-2882	6.9	18
248	Abstract 2983: A synthetic derivative of 1,2,3-triazole-pyrimidine hybrid reverses multidrug resistance mediated by MRP7 **2020**,		2
247	Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. *Drug Resistance Updates*, **2020**, 52, 100703	23.2	13
246	Multifaceted anti-colorectal tumor effect of digoxin on HCT8 and SW620 cells. *Gastroenterology Report*, **2020**, 8, 465-475	3.3	2
245	Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. *Drug Resistance Updates*, **2020**, 48, 100663	23.2	80

244	A multi-functionalized nanocomposite constructed by gold nanorod core with triple-layer coating to combat multidrug resistant colorectal cancer. *Materials Science and Engineering C*, **2020**, 107, 110224	8.3	11
243	Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. *Cancer Letters*, **2020**, 472, 132-141	9.9	8
242	Surmounting cancer drug resistance: New insights from the perspective of N-methyladenosine RNA modification. *Drug Resistance Updates*, **2020**, 53, 100720	23.2	38
241	Chloroquine against malaria, cancers and viral diseases. *Drug Discovery Today*, **2020**, 25, 2012-2012	8.8	23
240	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. *Pharmacology & Therapeutics*, **2020**, 216, 107672	13.9	31
239	Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing. *Molecular Cancer*, **2020**, 19, 147	42.1	15
238	Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators. *Journal of Medicinal Chemistry*, **2020**, 63, 15979-15996	8.3	12
237	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. *Frontiers in Pharmacology*, **2020**, 11, 1208	5.6	14
236	A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway. *Molecular Therapy - Oncolytics*, **2020**, 18, 137-148	6.4	4
235	Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. *Frontiers in Microbiology*, **2020**, 11, 1718	5.7	3
234	NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance. *Frontiers in Oncology*, **2020**, 10, 1219	5.3	5
233	Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. *Molecular Cancer*, **2020**, 19, 134	42.1	12
232	Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 865	5.7	12
231	Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway. *Frontiers in Oncology*, **2020**, 10, 1732	5.3	5
230	Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. *Signal Transduction and Targeted Therapy*, **2020**, 5, 193	21	27
229	BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. *Cancers*, **2020**, 12,	6.6	7
228	Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 601400	5.7	10
227	Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells. *Frontiers in Pharmacology*, **2020**, 11, 615824	5.6	8

226	Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia. *Frontiers in Oncology*, **2020**, 10, 588641	5.3	3
225	Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line. *Frontiers in Oncology*, **2020**, 10, 624954	5.3	4
224	Anti-cancer effect of Indanone-based thiazolyl hydrazone derivative on colon cancer cell lines. *International Journal of Biochemistry and Cell Biology*, **2019**, 110, 21-28	5.6	12
223	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	16
222	Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. *European Journal of Pharmacology*, **2019**, 863, 172611	5.3	18
221	Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. *European Journal of Medicinal Chemistry*, **2019**, 179, 849-862	6.8	20
220	Revisiting mTOR inhibitors as anticancer agents. *Drug Discovery Today*, **2019**, 24, 2086-2095	8.8	11
219	Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. *Frontiers in Oncology*, **2019**, 9, 313	5.3	17
218	Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. *Biochemical Pharmacology* , **2019**, 166, 120-127	6	35
217	Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy. *Molecular Pharmacology*, **2019**, 96, 73-89	4.3	12
216	EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy **2019**, 1-11		3
215	An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms. *Chemical Communications*, **2019**, 55, 3833-3836	5.8	6
214	From Antimicrobial to Anticancer Peptides: The Transformation of Peptides. *Recent Patents on Anti-Cancer Drug Discovery*, **2019**, 14, 70-84	2.6	18
213	Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. *Future Medicinal Chemistry*, **2019**,	4.1	24
212	BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy **2019**, 13-27		
211	circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. *Molecular Cancer*, **2019**, 18, 23	42.1	100
210	The targeting of non-coding RNAs by curcumin: Facts and hopes for cancer therapy (Review). *Oncology Reports*, **2019**, 42, 20-34	3.5	24
209	Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis. *Annals of the Rheumatic Diseases*, **2019**, 78, 1524-1535	2.4	14

208	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an Study. *Frontiers in Oncology*, **2019**, 9, 514	5.3	22
207	Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK. *Recent Patents on Anti-Cancer Drug Discovery*, **2019**, 14, 177-186	2.6	7
206	Design, synthesis and biological evaluation of selective survivin inhibitors. *Journal of Biomedical Research*, **2019**, 33, 82-100	1.5	1
205	Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. *Molecules*, **2019**, 24,	4.8	30
204	Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	16
203	The epigallocatechin gallate derivative Y reverses drug resistance mediated by the ABCB1 transporter both and. *Acta Pharmaceutica Sinica B*, **2019**, 9, 316-323	15.5	11
202	Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. *Cancer Letters*, **2019**, 442, 91-103	9.9	22
201	Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer. *Cancer Letters*, **2019** , 442, 104-112	9.9	22
200	Discovery of Novel Quinoline-Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity. *Journal of Medicinal Chemistry*, **2019**, 62, 993-1013	8.3	53
199	Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. *Cancer Letters*, **2019**, 440-441, 82-93	9.9	55
198	Y, an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone Resistance. *Frontiers in Pharmacology*, **2018**, 9, 1545	5.6	7
197	Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo. *Cancer Letters*, **2018**, 424, 19-29	9.9	31
196	Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. *Cellular Physiology and Biochemistry*, **2018**, 45, 1515-1528	3.9	34
195	Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors. *European Journal of Medicinal Chemistry*, **2018**, 149, 211-224	6.8	10
194	Comprehensive Synthesis of Amino Acid-Derived Thiazole Peptidomimetic Analogues to Understand the Enigmatic Drug/Substrate-Binding Site of P-Glycoprotein. *Journal of Medicinal Chemistry*, **2018**, 61, 834-864	8.3	15
193	Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. *Cancer Letters*, **2018**, 421, 186-198	9.9	66
192	Oncosis-inducing cyclometalated iridium(iii) complexes. *Chemical Science*, **2018**, 9, 5183-5190	9.4	60
191	Exploration of 1,2,3-triazole-pyrimidine hybrids as potent reversal agents against ABCB1-mediated multidrug resistance. *European Journal of Medicinal Chemistry*, **2018**, 143, 1535-1542	6.8	30

190	Discovery of a non-toxic [1,2,4]triazolo[1,5-a]pyrimidin-7-one (WS-10) that modulates ABCB1-mediated multidrug resistance (MDR). *Bioorganic and Medicinal Chemistry*, **2018**, 26, 5006-5017	3.4	10
189	TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. *Recent Patents on Anti-Cancer Drug Discovery*, **2018**, 13, 341-347	2.6	7
188	Pharmacotherapeutic Options for Philadelphia Chromosome- Positive CML. *Journal of Cancer Research Updates*, **2018**, 7, 49-58	1	
187	Patterned Synthesis of ZnO Nanorod Arrays for Nanoplasmonic Waveguide Applications. *Optics Communications*, **2018**, 411, 53-58	2	11
186	VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. *Frontiers in Pharmacology*, **2018**, 9, 1236	5.6	36
185	Modulating ROS to overcome multidrug resistance in cancer. *Drug Resistance Updates*, **2018**, 41, 1-25	23.2	238
184	A personalized and long-acting local therapeutic platform combining photothermal therapy and chemotherapy for the treatment of multidrug-resistant colon tumor. *International Journal of Nanomedicine*, **2018**, 13, 8411-8427	7.3	11
183	Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. *Frontiers in Pharmacology*, **2018**, 9, 1097	5.6	32
182	Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. *Biochemical Pharmacology*, **2018**, 158, 274-285	6	36
181	Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance. *Journal of Medicinal Chemistry*, **2018**, 61, 5988-6001	8.3	38
180	Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib. *Pharmacological Research*, **2017**, 119, 89-98	10.2	17
179	The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors. *Molecular Cancer Therapeutics*, **2017**, 16, 1021-1030	6.1	25
178	GSK1904529A, a Potent IGF-IR Inhibitor, Reverses MRP1-Mediated Multidrug Resistance. *Journal of Cellular Biochemistry*, **2017**, 118, 3260-3267	4.7	17
177	Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881. *Biochemical Pharmacology*, **2017**, 132, 29-37	6	22
176	2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations. *Journal of Cellular Biochemistry*, **2017**, 118, 2420-2429	4.7	5
175	A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway. *Journal of Medicinal Chemistry*, **2017**, 60, 1449-1468	8.3	75
174	Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. *Scientific Reports*, **2017**, 7, 42106	4.9	7
173	Establishment and characterization of arsenic trioxide resistant KB/ATO cells. *Acta Pharmaceutica Sinica B*, **2017**, 7, 564-570	15.5	12

172	Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. *Pharmacological Research*, **2017**, 121, 184-193	10.2	12
171	Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study. *Cancer Letters*, **2017**, 396, 145-154	9.9	39
170	Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4832-4837	2.9	10
169	Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance. *International Journal of Oncology*, **2017**, 51, 257-268	4.4	11
168	Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells. *Oncotarget*, **2017**, 8, 29760-29770	3.3	23
167	Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4698-4704	2.9	13
166	6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents. *Journal of Natural Products*, **2017**, 80, 2391-2398	4.9	23
165	The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. *Chemical Society Reviews*, **2017**, 46, 5771-5804	58.5	573
164	Autophagy and multidrug resistance in cancer. *Chinese Journal of Cancer*, **2017**, 36, 52		295
163	Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer. *Cancer Letters*, **2017**, 386, 100-109	9.9	28
162	CDX2 Stimulates the Proliferation of Porcine Intestinal Epithelial Cells by Activating the mTORC1 and Wnt/Catenin Signaling Pathways. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	19
161	Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: and studies. *Oncotarget*, **2017**, 8, 93785-93799	3.3	21
160	Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. *Scientific Reports*, **2016**, 6, 25694	4.9	42
159	Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-B Pathway in Colorectal Cancer. *Journal of Cellular Biochemistry*, **2016**, 117, 1471-81	4.7	31
158	Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 281-9	5.5	17
157	Cytokines in cancer drug resistance: Cues to new therapeutic strategies. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2016**, 1865, 255-65	11.2	91
156	1,2,3-Triazole-Dithiocarbamate Hybrids, a Group of Novel Cell Active SIRT1 Inhibitors. *Cellular Physiology and Biochemistry*, **2016**, 38, 185-93	3.9	7
155	Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. *Oncotarget*, **2016**, 7, 5877-91	3.3	21

154	Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. *Journal of Biomedical Research*, **2016**, 30, 120-133	1.5	9
153	Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. *Molecules*, **2016**, 21,	4.8	28
152	Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. *Drug Resistance Updates*, **2016**, 27, 14-29	23.2	362
151	Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria. *Journal of Medicinal Chemistry*, **2016**, 59, 5022-34	8.3	49
150	TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy. *Epigenomics*, **2016**, 8, 651-66	4.4	55
149	PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. *Cancer Letters*, **2016**, 383, 220-229	9.9	20
148	ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. *Chinese Journal of Cancer*, **2015**, 34, 115-20		16
147	Multidrug Resistance Proteins (MRPs) and Cancer Therapy. *AAPS Journal*, **2015**, 17, 802-12	3.7	123
146	The reversal of antineoplastic drug resistance in cancer cells by β-elemene. *Chinese Journal of Cancer*, **2015**, 34, 488-95		25
145	Exploring naturally occurring ivy nanoparticles as an alternative biomaterial. *Acta Biomaterialia*, **2015**, 25, 268-83	10.8	23
144	Silver nanoparticles: synthesis, properties, and therapeutic applications. *Drug Discovery Today*, **2015** , 20, 595-601	8.8	541
143	P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae **2015**, 593-619		
142	B4G2 induces mitochondrial apoptosis by the ROS-mediated opening of Ca(2+)-dependent permeability transition pores. *Cellular Physiology and Biochemistry*, **2015**, 37, 838-52	3.9	13
141	Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. *Cancers*, **2015**, 7, 2360-71	6.6	143
140	Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance. *Marine Drugs*, **2015**, 13, 2267-86	6	15
139	A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. *Oncotarget*, **2015**, 6, 39276-91	3.3	15
138	Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents. *Oncotarget*, **2015**, 6, 24277-90	3.3	33
137	ABC Transporter Modulatory Drugs from Marine Sources: A New Approach to Overcome Drug Resistance in Cancer. *Resistance To Targeted Anti-cancer Therapeutics*, **2015**, 183-208	0.3	2

136	Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells. *International Journal of Oncology*, **2015**, 46, 2029-38	4.4	27
135	Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). *Biochemical Pharmacology*, **2015**, 93, 266-76	6	28
134	The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. *Drug Resistance Updates*, **2015**, 18, 1-17	23.2	463
133	The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. *Oncotarget*, **2015**, 6, 510-21	3.3	26
132	Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. *Oncotarget*, **2015**, 6, 17738-52	3.3	13
131	5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/Ecatenin/MMP-7 signaling pathway. *Oncotarget*, **2015**, 6, 25975-87	3.3	33
130	IKK inhibition increases bortezomib effectiveness in ovarian cancer. *Oncotarget*, **2015**, 6, 26347-58	3.3	21
129	Bufalin Induces Apoptosis of MDA-MB-231 Cell Through Activation of JNK/p53 Pathway. *Journal of Cancer Research Updates*, **2015**, 4, 47-53	1	1
128	Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. *International Journal of Biochemistry and Cell Biology*, **2014**, 51, 111-9	5.6	26
127	Fragmented polymer nanotubes from sonication-induced scission with a thermo-responsive gating system for anti-cancer drug delivery. *Journal of Materials Chemistry B*, **2014**, 2, 1327-1334	7.3	18
126	Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. *Biochemical Pharmacology*, **2014**, 90, 367-78	6	46
125	Synthesis and evaluation of sulfonylethyl-containing phosphotriesters of 3'-azido-3'-deoxythymidine as anticancer prodrugs. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 5747-58	2.4	4
124	CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. *Biochemical Pharmacology*, **2014**, 91, 144-56	6	15
123	Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates. *ACS Medicinal Chemistry Letters*, **2014**, 5, 797-802	4.3	43
122	Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid. *Journal of Medicinal Chemistry*, **2014**, 57, 4058-72	8.3	39
121	AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. *Cancer Letters*, **2014**, 350, 61-8	9.9	29
120	PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. *Acta Pharmaceutica Sinica B*, **2014**, 4, 202-7	15.5	18
119	ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2. *Journal of Cellular Biochemistry*, **2014**, 115, 1381-91	4.7	16

118	Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. *Biochemical Pharmacology*, **2014**, 89, 52-61	6	43
117	Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. *Molecules*, **2014**, 19, 13848-77	4.8	83
116	Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. *Chinese Journal of Cancer*, **2014**, 33, 223-30		35
115	Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. *Oncology Reports*, **2014**, 31, 1605-12	3.5	22
114	Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. *Oncology Reports*, **2014**, 31, 858-66	3.5	41
113	Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. *International Journal of Oncology*, **2014**, 44, 1634-42	4.4	26
112	Lamellarin O, a pyrrole alkaloid from an Australian marine sponge, Ianthella sp., reverses BCRP mediated drug resistance in cancer cells. *Marine Drugs*, **2014**, 12, 3818-37	6	50
111	miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer. *Molecular Cancer Therapeutics*, **2014**, 13, 3137-51	6.1	63
110	Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). *Future Oncology*, **2014**, 10, 1827-41	3.6	24
109	Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. *Cancers*, **2014**, 6, 1925-52	6.6	46
108	WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells. *Cancer Science*, **2014**, 105, 1071-8	6.9	20
107	In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1. *British Journal of Pharmacology*, **2014**, 171, 5845-57	8.6	42
106	Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study. *Molecular Cancer Therapeutics*, **2014**, 13, 714-23	6.1	35
105	Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells. *European Journal of Pharmacology*, **2014**, 733, 34-44	5.3	15
104	Triterpenoids as reversal agents for anticancer drug resistance treatment. *Drug Discovery Today*, **2014**, 19, 482-8	8.8	48
103	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. *Oncotarget*, **2014**, 5, 4529-42	3.3	37
102	Sildenafil Enhances the Anticancer Activity of Paclitaxel in an ABCB1-Mediated Multidrug Resistance Xenograft Mouse Model. *Journal of Cancer Research Updates*, **2014**, 3, 169-173	1	1
101	Cytokine detection by flow cytometry. *Methods in Molecular Biology*, **2014**, 1172, 235-42	1.4	5

100	Anticancer Activity of Five Traditionally Used Medicinal Plants Extracts. *Journal of Cancer Research Updates*, **2014**, 3, 103-107	1	0
99	Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristine. *Anticancer Research*, **2014**, 34, 4767-73	2.3	12
98	Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. *International Journal of Cancer*, **2013**, 132, 224-35	7.5	35
97	New phenstatin-fatty acid conjugates: synthesis and evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5119-22	2.9	8
96	The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. *Biochemical Pharmacology*, **2013**, 85, 514-24	6	69
95	Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells. *Biochemical Pharmacology*, **2013**, 85, 1257-68	6	25
94	Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2. *European Journal of Pharmaceutical Sciences*, **2013**, 49, 441-50	5.1	22
93	PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. *Cancer Chemotherapy and Pharmacology*, **2013**, 72, 189-99	3.5	42
92	Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. *Cancer Letters*, **2013**, 328, 307-17	9.9	92
91	Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells. *Anti-Cancer Drugs*, **2013**, 24, 441-54	2.4	6
90	Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). *Oncology Reports*, **2013**, 29, 2479-85	3.5	31
89	Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. *PLoS ONE*, **2013**, 8, e55576	3.7	30
88	bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). *PLoS ONE*, **2013**, 8, e74573	3.7	11
87	Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants. *Frontiers in Pharmacology*, **2013**, 4, 82	5.6	13
86	BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. *PLoS ONE*, **2013**, 8, e54181	3.7	18
85	Antineoplastic activity of Holoptelea integrifolia (Roxb.) Planch bark extracts (in vitro). *Pakistan Journal of Pharmaceutical Sciences*, **2013**, 26, 1151-6	0.4	3
84	GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. *Biochemical Pharmacology*, **2012**, 83, 1613-22	6	55
83	PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. *Cancer Science*, **2012**, 103, 1531-7	6.9	34

82	The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. *Molecular Cancer Therapeutics*, **2012**, 11, 2033-44	6.1	69
81	Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. *Breast Cancer Research and Treatment*, **2012**, 135, 737-47	4.4	73
80	Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. *Molecular Pharmacology*, **2012**, 82, 47-58	4.3	79
79	Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. *Drug Resistance Updates*, **2012**, 15, 70-80	23.2	128
78	Design, synthesis and biological evaluation of N-arylphenyl-2,2-dichloroacetamide analogues as anti-cancer agents. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 7268-71	2.9	15
77	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. *Biochemical Pharmacology*, **2012**, 84, 766-74	6	20
76	BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. *Molecular Pharmaceutics*, **2012**, 9, 3147-59	5.6	38
75	Current status on marine products with reversal effect on cancer multidrug resistance. *Marine Drugs*, **2012**, 10, 2312-21	6	56
74	Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202. *Molecular Pharmaceutics*, **2012**, 9, 1971-82	5.6	33
73	Multidrug resistance associated proteins in multidrug resistance. *Chinese Journal of Cancer*, **2012**, 31, 58-72		165
72	Autophagy and transporter-based multi-drug resistance. *Cells*, **2012**, 1, 558-75	7.9	44
71	Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. *Anti-Cancer Drugs*, **2012**, 23, 865-73	2.4	21
70	Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. *Chinese Journal of Cancer*, **2012**, 31, 110-8		49
69	Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu. *Molecular Pharmaceutics*, **2011**, 8, 1687-97	5.6	39
68	Biosynthesis of Nanoparticles by Microorganisms and Their Applications. *Journal of Nanomaterials*, **2011**, 2011, 1-16	3.2	396
67	The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. *PLoS ONE*, **2011**, 6, e19329	3.7	62
66	Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells. *Oncology Letters*, **2011**, 2, 549-556	2.6	4
65	Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. *FEBS Journal*, **2011**, 278, 3226-45	5.7	193

64	Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6495-9	2.9	6
63	Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. *Cancer Research*, **2011**, 71, 3029-41	10.1	139
62	Roles of sildenafil in enhancing drug sensitivity in cancer. *Cancer Research*, **2011**, 71, 3735-8	10.1	52
61	Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. *Cancer Research*, **2011**, 71, 3649-57	10.1	54
60	Revisiting the ABCs of multidrug resistance in cancer chemotherapy. *Current Pharmaceutical Biotechnology*, **2011**, 12, 570-94	2.6	155
59	Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. *Cancer Research*, **2010**, 70, 7981-91	10.1	255
58	Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. *Biochemical Pharmacology*, **2010**, 79, 154-61	6	71
57	Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. *Biochemical Pharmacology*, **2010**, 80, 1497-506	6	49
56	BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. *Leukemia Research*, **2010**, 34, 1255-68	2.7	208
55	Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). *PLoS ONE*, **2009**, 4, e7520	3.7	59
54	Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. *Cancer Research*, **2009**, 69, 178-84	10.1	105
53	Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. *Clinical Cancer Research*, **2009**, 15, 1762-9	12.9	67
52	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. *Biochemical Pharmacology*, **2009**, 77, 781-93	6	63
51	Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. *Biochemical Pharmacology*, **2009**, 77, 993-1001	6	57
50	Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. *Biochemical Pharmacology*, **2009**, 78, 153-61	6	179
49	Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. *Biochemical Pharmacology*, **2009**, 78, 355-64	6	25
48	RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. *Cancer Letters*, **2009**, 276, 189-95	9.9	68
47	Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. *Cancer Letters*, **2009**, 279, 74-83	9.9	99

46	Sipholane triterpenoids: chemistry, reversal of ABCB1/P-glycoprotein-mediated multidrug resistance, and pharmacophore modeling. *Journal of Natural Products*, **2009**, 72, 1291-8	4.9	44
45	The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. *Oncology Reports*, **2009**, 21, 483-9	3.5	42
44	Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. *Cancer Research*, **2008**, 68, 7905-14	10.1	321
43	Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing. *Journal of Proteome Research*, **2008**, 7, 4784-91	5.6	25
42	Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. *Leukemia Research*, **2008**, 32, 799-809	2.7	49
41	Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids. *Journal of Natural Products*, **2007**, 70, 928-31	4.9	52
40	Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. *Cancer Research*, **2007**, 67, 11012-20	10.1	252
39	Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. *Cancer Science*, **2007**, 98, 1373-80	6.9	51
38	ABCC10, ABCC11, and ABCC12. *Pflugers Archiv European Journal of Physiology*, **2007**, 453, 675-84	4.6	100
37	Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. *Oncology Reports*, **2007**,	3.5	4
36	Reversal effect of BM-cyclin 1 on multidrug resistance in C-A120 cells. *Anti-Cancer Drugs*, **2007**, 18, 1015-21	2.1	2
35	Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. *Oncology Reports*, **2007**, 17, 969-76	3.5	41
34	Isolation and characterization of arsenite-resistant human epidermoid carcinoma KB cells. *Oncology Reports*, **2007**, 18, 721-7	3.5	7
33	Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. *Cancer Biology and Therapy*, **2006**, 5, 39-47	4.6	127
32	Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). *Molecular Pharmacology*, **2005**, 67, 545-57	4.3	137
31	Analysis of the in vivo functions of Mrp3. *Molecular Pharmacology*, **2005**, 68, 160-8	4.3	155
30	Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. *Cancer Research*, **2004**, 64, 4927-30	10.1	177
29	MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. *Journal of Biological Chemistry*, **2003**, 278, 29509-14	5.4	190

28	Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). *Molecular Pharmacology*, **2003**, 63, 351-8	4.3	149
27	Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. *Cancer Research*, **2003**, 63, 4048-54	10.1	218
26	Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice. *Molecular and Cellular Biology*, **2002**, 22, 5212-21	4.8	51
25	Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. *Oncology Reports*, **2002**, 9, 839	3.5	
24	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. *Cancer Research*, **2002**, 62, 3144-50	10.1	224
23	Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. *Oncology Reports*, **2002**, 9, 839-44	3.5	8
22	Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). *Cancer Research*, **2002**, 62, 6172-7	10.1	175
21	Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. *International Journal of Cancer*, **2001**, 93, 107-13	7.5	57
20	Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. *International Journal of Cancer*, **2001**, 93, 869-74	7.5	112
19	MRP subfamily transporters and resistance to anticancer agents. *Journal of Bioenergetics and Biomembranes*, **2001**, 33, 493-501	3.7	129
18	Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells. *Japanese Journal of Cancer Research*, **2001**, 92, 886-95		54
17	Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. *Journal of Biological Chemistry*, **2001**, 276, 23197-206	5.4	55
16	Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. *Journal of Biological Chemistry*, **2001**, 276, 33747-54	5.4	308
15	Multidrug resistance reversal activity of taxoids from Taxus cuspidata in KB-C2 and 2780AD cells. *Japanese Journal of Cancer Research*, **2000**, 91, 638-42		15
14	Reversal of P-glycoprotein and multidrug-resistance protein-mediated drug resistance in KB cells by 5-O-benzoylated taxinine K. *Molecular Pharmacology*, **2000**, 58, 1563-9	4.3	27
13	Functional comparison between YCF1 and MRP1 expressed in Sf21 insect cells. *Biochemical and Biophysical Research Communications*, **2000**, 270, 608-15	3.4	19
12	Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. *Journal of the National Cancer Institute*, **1999**, 91, 1647-53	9.7	164
11	Reversal of multidrug resistance in human carcinoma cell line by agosterols, marine spongean sterols. *Tetrahedron*, **1999**, 55, 13965-13972	2.4	38

10	An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells. *Cancer Letters*, **1999**, 138, 13-22	9.9	14
9	Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). *FEBS Letters*, **1999**, 456, 327-31	3.8	127
8	Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. *Molecular Pharmacology*, **1999**, 56, 1219-28	4.3	158
7	Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of Spongia sp.. *Tetrahedron Letters*, **1998**, 39, 6303-6306	2	58
6	Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. *Cancer Letters*, **1998**, 129, 69-76	9.9	27
5	Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078. *Cancer Letters*, **1998**, 130, 175-82	9.9	28
4	An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. *Experimental Cell Research*, **1998**, 240, 312-20	4.2	46
3	Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells. *Biochemical and Biophysical Research Communications*, **1997**, 236, 586-90	3.4	44
2	Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells. *Biochemical and Biophysical Research Communications*, **1996**, 226, 158-65	3.4	29
1	Anticancer Activity of Oldenlandia Diffusa & Viola Philippica Car. *Journal of Cancer Research Updates*,	1	1